PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SPRY vs. STZ
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SPRY and STZ is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

SPRY vs. STZ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Silverback Therapeutics Inc (SPRY) and Constellation Brands, Inc. (STZ). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%SeptemberOctoberNovemberDecember2025February
-55.04%
-12.34%
SPRY
STZ

Key characteristics

Sharpe Ratio

SPRY:

0.79

STZ:

-1.00

Sortino Ratio

SPRY:

1.42

STZ:

-1.19

Omega Ratio

SPRY:

1.17

STZ:

0.81

Calmar Ratio

SPRY:

0.56

STZ:

-0.68

Martin Ratio

SPRY:

2.81

STZ:

-1.88

Ulcer Index

SPRY:

17.62%

STZ:

14.35%

Daily Std Dev

SPRY:

63.11%

STZ:

26.94%

Max Drawdown

SPRY:

-95.20%

STZ:

-75.46%

Current Drawdown

SPRY:

-81.39%

STZ:

-34.12%

Fundamentals

Market Cap

SPRY:

$1.09B

STZ:

$31.81B

EPS

SPRY:

-$0.50

STZ:

$3.75

Total Revenue (TTM)

SPRY:

$2.57M

STZ:

$10.18B

Gross Profit (TTM)

SPRY:

$2.43M

STZ:

$5.20B

EBITDA (TTM)

SPRY:

-$50.25M

STZ:

$1.61B

Returns By Period

In the year-to-date period, SPRY achieves a 6.54% return, which is significantly higher than STZ's -19.90% return.


SPRY

YTD

6.54%

1M

-17.05%

6M

-13.27%

1Y

47.89%

5Y*

N/A

10Y*

N/A

STZ

YTD

-19.90%

1M

-1.38%

6M

-27.50%

1Y

-27.51%

5Y*

-1.19%

10Y*

5.87%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SPRY vs. STZ — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRY
The Risk-Adjusted Performance Rank of SPRY is 7070
Overall Rank
The Sharpe Ratio Rank of SPRY is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of SPRY is 6969
Sortino Ratio Rank
The Omega Ratio Rank of SPRY is 6767
Omega Ratio Rank
The Calmar Ratio Rank of SPRY is 7070
Calmar Ratio Rank
The Martin Ratio Rank of SPRY is 7272
Martin Ratio Rank

STZ
The Risk-Adjusted Performance Rank of STZ is 55
Overall Rank
The Sharpe Ratio Rank of STZ is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of STZ is 88
Sortino Ratio Rank
The Omega Ratio Rank of STZ is 66
Omega Ratio Rank
The Calmar Ratio Rank of STZ is 99
Calmar Ratio Rank
The Martin Ratio Rank of STZ is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SPRY vs. STZ - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Silverback Therapeutics Inc (SPRY) and Constellation Brands, Inc. (STZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SPRY, currently valued at 0.79, compared to the broader market-2.000.002.000.79-1.00
The chart of Sortino ratio for SPRY, currently valued at 1.42, compared to the broader market-4.00-2.000.002.004.006.001.42-1.19
The chart of Omega ratio for SPRY, currently valued at 1.17, compared to the broader market0.501.001.502.001.170.81
The chart of Calmar ratio for SPRY, currently valued at 0.56, compared to the broader market0.002.004.006.000.56-0.68
The chart of Martin ratio for SPRY, currently valued at 2.81, compared to the broader market-10.000.0010.0020.0030.002.81-1.88
SPRY
STZ

The current SPRY Sharpe Ratio is 0.79, which is higher than the STZ Sharpe Ratio of -1.00. The chart below compares the historical Sharpe Ratios of SPRY and STZ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-2.000.002.004.006.00SeptemberOctoberNovemberDecember2025February
0.79
-1.00
SPRY
STZ

Dividends

SPRY vs. STZ - Dividend Comparison

SPRY has not paid dividends to shareholders, while STZ's dividend yield for the trailing twelve months is around 2.30%.


TTM2024202320222021202020192018201720162015
SPRY
Silverback Therapeutics Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
STZ
Constellation Brands, Inc.
2.30%1.77%1.44%1.36%1.21%1.37%1.58%1.70%0.86%0.98%0.65%

Drawdowns

SPRY vs. STZ - Drawdown Comparison

The maximum SPRY drawdown since its inception was -95.20%, which is greater than STZ's maximum drawdown of -75.46%. Use the drawdown chart below to compare losses from any high point for SPRY and STZ. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-81.39%
-34.12%
SPRY
STZ

Volatility

SPRY vs. STZ - Volatility Comparison

Silverback Therapeutics Inc (SPRY) has a higher volatility of 15.95% compared to Constellation Brands, Inc. (STZ) at 8.80%. This indicates that SPRY's price experiences larger fluctuations and is considered to be riskier than STZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
15.95%
8.80%
SPRY
STZ

Financials

SPRY vs. STZ - Financials Comparison

This section allows you to compare key financial metrics between Silverback Therapeutics Inc and Constellation Brands, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab